Track topics on Twitter Track topics that are important to you
French biotech company Cellectis announced today that Dr Mathieu Simon is retiring as executive vice…
Cellectis spin-off Calyxt has launched a €41M follow-on round after settling the lawsuit it recently brought against Bayer CropScience, for breach of a license agreement for access to patents for...
Several protocol changes were made by Cellectis in an effort to advance its Phase I study for its chimeric antigen receptor T -More-
Cellectis submitted an investigational new drug application to the FDA seeking approval to begin its early-stage trial to ass -More-
Cellectis announced it had appointed Stefan Scherer to the role of senior vice president Clinical Development and deputy chief medical officer.
Cellectis has found some sure financial footing that will support its efforts through the remainder of the year. The company secured $163.7 million in an initial public offering to develop CART-T prod...
Stefan Scherer has been appointed senior vice president of clinical development and deputy chief medical officer of Cellectis (NASDAQ: CLLS). He comes to the French cell therapy developer from Novarti...
Cellectis has submitted an IND for off-the-shelf T-cell candidate UCART22, an allogeneic investigational therapy designed to treat leukemia.
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools, meganucleases. These molecular scissors enable targeted modifications ...
Cellectis stem cells, is a business unit within the Cellectis group and is a global leader in stem cell technology. Cellectis stem cells, created in November 2011 from Cellartis A...
Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in June 2008. It provides life science researchers with ready-to-use research tools for genome customization. ...
Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in in vivo genome surgery a...
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applicat...
We have published hundreds of Cellectis news stories on BioPortfolio along with dozens of Cellectis Clinical Trials and PubMed Articles about Cellectis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cellectis Companies in our database. You can also find out about relevant Cellectis Drugs and Medications on this site too.
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...